FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 338:1624-1626 May 28, 1998 Number 22 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Kuivenhoven, J. A. PubMed Citation

To the Editor: The study of polymorphism of the gene for cholesteryl ester transfer protein (CETP), reported by Kuivenhoven et al. (Jan. 8 issue),¹ has negative implications in the era of managed care and cost containment. The authors demonstrated that in a population of middle-aged men, only those with a certain CETP genotype had a benefit from pravastatin therapy in the form of a delay in the angiographic progression of coronary atherosclerosis. This group of patients represented about one third of those studied. The implication is that someday only patients with a certain genotype will be given a . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Freeman, D. J, Samani, N. J, Wilson, V., McMahon, A. D, Braund, P. S, Cheng, S., Caslake, M. J, Packard, C. J, Gaffney, D., on behalf of the West of Scotland Study Group, (2003). A polymorphism of the cholesteryl ester transfer protein gene predicts cardiovascular events in non-smokers in the West of Scotland Coronary Prevention Study. Eur Heart J 24: 1833-1842 [Abstract] [Full Text]